Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Acne Treatment Devices Heat Up Competition With ERSP-Cleared Claims

This article was originally published in The Tan Sheet

Executive Summary

The rise of beauty devices in recent years has generated buzz, but also skepticism about claims. In a review of La Lumiere’s illuMask home-use acne-treatment device, the Electronic Retailing Self-Regulatory Program finds the performance claims adequately substantiated, consistent with previous decisions.

You may also be interested in...



‘The Dark Side’ Of Green Packaging: Cosmetics Technical Expert On Challenges And Potential Risks

Presenting at the Independent Beauty Association’s Cosmetic Technical/Regulatory Forum, Product Integrity Laboratory’s Howard Baker dug into the less-discussed aspects of green packaging that “could damage your brand’s reputation, cause regulatory and legal problems, and severely harm the economics of your business.”

CIR ‘Watchdog’ Women’s Voices For The Earth To Remain On Guard In 2021

NGO says the Expert Panel for Cosmetic Ingredient Safety’s conclusion on methylisothiazolinone in 2020 was among decisions “not in the interest of public health.” However, other assessments highlighted by the group suggest that the Cosmetic Ingredient Review is working as an open forum for public input and discussion.

Estee Lauder Companies To Make ‘Abnormal Beauty’ Its Own

The beauty titan will increase its stake in DECIEM to 76% in a deal valuating The Ordinary skin-care owner at $2.2bn. Remaining interests will be acquired after three years, according to the announcement.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel